Academician Han Zhongchao of Biopharmaceutical Quality Science Congress Hanzhong Chaojin's "Tianjin Model"

On August 11, 2022, the 3022 3rd QBD Biopharmaceutical Quality Science Conference jointly organized by the China Medical Quality Management Association and Biovalley, Baiao Valley Biovalley was held in Beijing. As well as the four major parallel forums of global pharmaceutical policies and regulations, more than 1,000 colleagues in the industry and more than 70 industry authoritative coffees have been convened to jointly explore and discuss. It aims to adhere to the quality of drug quality in domestic enterprises, help the management system for the management system, and accompany international norms. At this meeting, Academician Han Zhongchao, the chairman of the Han family, delivered a speech with the theme of "R & D and Application of Stem Cell Drugs", and once again mentioned the "Tianjin Model" of cell science and technology, research, research, and research.

Tianjin, the largest port city in North China, introduced the stem cell industry with its own unique advantages, and gradually implemented the stem cell industry to form a preliminary industrial cluster. This leads and affects the development of overall stem cell research and industrialization in China. The industry in the industry refers to the model of stem cell transformation medicine as "Tianjin Model".

As early as 2011, Professor Chen Haidan, Peking University, published an article in the magazine of "STEM Cells Translational Medicine", using the "technical system" as a framework to analyze the "Tianjin Model" of stem cell transformation medicine and discuss it for cell therapy for cell therapy The influence of the industry. The article generally believes that the "Tianjin Model" represents a microcosm of China's stem cell research and provides rich experience in the development of stem cell transformation medicine. A series of original contributions made by the "Tianjin Model" in basic research, disease treatment, and industrialization are also known as the pioneering innovation of the stem cell industry in the industry.

In the past ten years, the development of clinical trials of stem cells has been relatively rapid, providing new strategies for the treatment of refractory diseases. Han's joint scientific research team led by Academician Han Zhongchao made many breakthroughs in major projects in many cell fields, and the earliest establishment of patented technologies in the germination of germinated stem cell libraries and large -scale preparation of umbilical cord placenta. The leading position. Since 2015, various national ministries and commissions have introduced a series of policies and technical guidance documents that support the research and development and transformation of stem cell technology, which reflects the state's determination to regulate the supervision of stem cells and comprehensive policy support. It has actively promoted the field of stem cells from disorderly to orderly to order Order healthy development.

Data show that as of July 31, 2022, 254 clinical research on cord cord germinated stem cells between cord cords. With the continuous breakthrough of research, it will usher in a stage of high -speed growth in the transformation of scientific research results. Nowadays, the first year of innovation and internationalization in the field of regeneration medicine is approaching. When innovation becomes the strongest voice of medicine, stem cells from theoretical basis to technological transformation and application, adhering to the quality of domestic stem cell drug research and development, will undoubtedly become a new challenge for quality people and drug administration registrars. The stem cell regeneration medicine represented by stem cell technology is the most watched medical development in the past ten years. It has major clinical application value and is known as the most likely to achieve revolutionary breakthrough in the 21st century biological and medical technology. In this global trend of biotechnology, Academician Han Zhongchao said: "In the field of regeneration medicine, my country has not lagged behind, and even leads the study of biomedical research in mesenchymal stem cells, and has broad application prospects."

It is understood that Academician Han Zhongchao has been engaged in scientific research for a long time and has served as the president of the Hematology Hospital (Institute of Hematology), China Academy of Medical Sciences. Fund projects and more than 20 research and development projects such as high -tech industrialization demonstration engineering projects of the National Planning Commission's "Industrialization Base" of the State Planning Commission.

The application basic research, industrial and clinical transformation applications of hematology, vascular biology, and stem cell regeneration medical technology in the Department of Medicine have achieved remarkable achievements. Editor -in -chief and participated in 8 monographs and 10 Chinese monographs, published more than 700 academic papers, among which more than 270 articles were published in international SCI magazines such as Lancet and Blood. More than 60 invention patents have been applied for, and 30 domestic and foreign science and technology awards have been won.

After 15 years of long -term accumulation and development, Beijing Han Family Union Biotechnology Co., Ltd. has achieved significant achievements in the field of regeneration medicine. It has independently developed more than 10 new stem cell drugs. The five indications approved by IND have entered the clinic During the experimental phase, where the light of traditional medicine could not be shined, it brought new light to patients through cell technology. Under the leadership of Academician Han Zhongchao, Han Family jointly exerted its own scientific research and hard work in the field of regeneration medicine. In order to explore science, the healthy development of human life, and the future.

- END -